HELE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HELE is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some near-term technical strength and an attractive options skew, but the core business fundamentals are still weak with declining revenue, negative net income, and shrinking margins in the latest quarter. Analyst targets have improved recently, but the overall Wall Street stance remains only Neutral/Hold, not a clear buy. Given the user's impatience and desire for a direct decision, the best call is to hold off rather than buy now.
HELE is showing a mixed-to-slightly bullish short-term setup. The MACD histogram is positive at 0.532, which supports ongoing momentum, but it is contracting, so strength is not accelerating. RSI_6 at 71.571 suggests the stock is near overbought conditions even though it is described as neutral in the data. Moving averages are converging, which usually signals an indecisive trend rather than a strong breakout. Price is around 22.87 in pre-market, above the pivot of 21.648 and below first resistance at 24.341. That places the stock in the middle of the current range with limited immediate upside before resistance.
["Recent analyst price target increases from UBS and Canaccord", "Canaccord noted sequential sales improvement and strong demand for key brands like Osprey, Braun, and Olive & June", "Pre-market trading above the pivot level suggests some short-term support", "Options flow is slightly call-skewed, which is mildly constructive"]
["No news in the recent week, so there is no fresh event-driven catalyst", "Latest quarter revenue declined 3.27% year over year", "Net income turned more negative, down 209.13% year over year", "EPS also deteriorated sharply year over year", "Gross margin fell 8.13% year over year, showing weaker profitability", "Analyst ratings remain only Neutral/Hold overall", "No meaningful hedge fund, insider, politician, or congress buying support was identified", "Stock trend model suggests weakness over the next month"]
In 2026/Q4, Helen of Troy posted weaker operating results. Revenue fell to 470.0 million, down 3.27% year over year, while net income dropped to -55.6 million and EPS fell to -2.41, both sharply worse than last year. Gross margin also compressed to 44.61%, down 8.13% year over year. The latest quarter season is 2026/Q4, and the financial picture points to ongoing profitability pressure despite some sequential sales improvement mentioned by analysts.
Recent analyst sentiment has improved slightly in price targets, with UBS raising its target to $25 from $16 and Canaccord raising to $23 from $18. However, both firms kept neutral-type ratings: UBS stayed Neutral and Canaccord stayed Hold. Earlier, UBS had cut its target to $16 and Canaccord had cut to $18, so the target revisions are positive, but the overall Wall Street view remains cautious. Pros: improving sales momentum, strong brand demand, and higher targets. Cons: weak earnings quality, margin compression, and no broad upgrade to Buy.
